The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksTissue Regenix Group Regulatory News (TRX)

Share Price Information for Tissue Regenix Group (TRX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 61.50
Bid: 61.00
Ask: 62.00
Change: 0.00 (0.00%)
Spread: 1.00 (1.639%)
Open: 61.50
High: 61.50
Low: 61.50
Prev. Close: 61.50
TRX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Holding(s) in Company

17 Dec 2009 14:47

RNS Number : 3180E
Oxeco PLC
17 December 2009
 



TR-1: notification of major interests in shares 

1. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

OXECO PLC

2. Reason for the notification   (please tick the appropriate box or boxes)

An acquisition or disposal of voting rights 

X

An acquisition or disposal of financial instruments which may result in the acquisition of shares already issued to which voting rights are attached

An event changing the breakdown of voting rights

Other (please specify):

3. Full name of person(s) subject to the notification obligation:

Barnard Nominees Limited

4. Full name of shareholder(s) (if different from 3.):

Nora Powell

5. Date of the transaction (and date on which the threshold is crossed or reached if different):

16/12/2009

6. Date on which issuer notified:

17/12/2009

7. Threshold(s) that is/are crossed or reached:

19%

8. Notified details:

Voting rights attached to shares

A: Voting rights attached to shares

Class/type of shares 

 if possible using the ISIN CODE

Situation previous to the Triggering transaction 

Resulting situation after the triggering transaction

Number of Shares 

Number of Voting Rights viii

Number of shares 

Number of voting rights ix

% of voting rights

Direct

Direct x

Indirect xi

Direct

Indirect

Oridinary Share of 0.1p each 

ISIN - GB00B1J5QT30

Nil

Nil

116,000,000

116,000,000

19.3%

B: Financial Instruments

Resulting situation after the triggering transaction xii

Type of financial instrument 

Expiration date xiii

Exercise/ Conversion Period/ Date xiv 

Number of voting rights that may be acquired if the instrument is exercised/ converted. 

% of voting rights

Total (A+B)

Number of voting rights

% of voting rights

116,000,000

19.3%

9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable xv:

Proxy Voting:

10. Name of the proxy holder:

11. Number of voting rights proxy holder will cease to hold:

12. Date on which proxy holder will cease to hold voting rights:

13. Additional information:

14. Contact name:

Michael Barnard

15. Contact telephone number:

01268 493333

Annex Notification Of Major Interests In Shares xvi

A: Identity of the person or legal entity subject to the notification obligation

Full name (including legal form for legal entities)

Contact address (registered office for legal entities)

Phone number 

Other useful information (at least legal representative for legal persons)

 

B:  Identity of the notifier, if applicable xvii

Full name 

Michael Barnard

Contact address 

17-21 New Century Road,

 Laindon, Basildon SS15 6AG

Phone number 

01268 493333

Other useful information (e.g. functional relationship with the person or legal entity subject to the notification obligation)

 

C: Additional information

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
HOLTRBITMMIBBIL
Date   Source Headline
25th Apr 20242:27 pmRNSResult of AGM
10th Apr 20247:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Six consecutive periods of >20% growth
5th Apr 20243:52 pmRNSHolding(s) in Company
19th Mar 20247:00 amRNSFinal results for the year ended 31 December 2023
1st Mar 20247:00 amRNSNotice of Results
6th Feb 20247:00 amRNSFirst EU shipment & new distributor agreements
29th Jan 20243:02 pmRNSHolding(s) in Company
25th Jan 20247:00 amRNSTrading update for 2023
23rd Jan 20245:24 pmRNS2023 LTIP Grant
22nd Nov 20234:36 pmRNSHolding(s) in Company
30th Oct 20237:00 amRNSHPRA approval & distribution agreement in Spain
18th Sep 202310:40 amEQSHardman & Co Research on Tissue Regenix (TRX): Continuing postive momentum 1H'23
15th Sep 20234:30 pmRNSDirector/PDMR Shareholding
5th Sep 20237:01 amRNSNew sports medicine product launch
5th Sep 20237:00 amRNSInterim results
31st Aug 20231:45 pmRNSExercise of Options and Total Voting Rights
21st Aug 20237:00 amRNSNotice of interim results
17th Jul 20237:00 amRNSHalf-Year Trading Update
10th Jul 20237:00 amRNSDistribution agreement for OrthoPure® XT in the UK
25th May 20237:00 amRNSDistribution agreement with Australian Allografts
9th May 202312:00 pmRNSHolding(s) in Company
27th Apr 202312:35 pmRNSResult of AGM, Share Reorganisation &TVR
18th Apr 20237:00 amRNSProposed Share Reorganisation Timetable
5th Apr 20232:55 pmEQSHardman & Co Research on Tissue Regenix (TRX): Turning profitable and cash-generative
5th Apr 20237:00 amRNSCEO and CFO Share Purchases
30th Mar 20237:00 amRNSHolding(s) in Company
21st Mar 20237:00 amRNSFinal results for the year ended 31 December 2022
6th Mar 20237:00 amRNSNotice of results and Investor presentation
31st Jan 20237:01 amRNSTrading update for 2022
31st Jan 20237:00 amRNSChange of Adviser
18th Jan 202310:06 amRNSHolding(s) in Company
18th Jan 20237:00 amRNSChinese distribution agreement for OrthoPure® XT
7th Dec 20227:00 amRNSProduct launch in dCELL® division
22nd Nov 20227:00 amRNSDistribution agreement - OrthoPure® XT in Germany
14th Nov 20226:05 pmRNSHolding(s) in Company
7th Nov 20222:35 pmRNSHolding(s) in Company
29th Sep 202210:13 amRNSDirector/PDMR Shareholding
27th Sep 20227:15 amEQSHardman & Co Research on Tissue Regenix (TRX): Operating leverage
7th Sep 20227:00 amRNSHalf-year Report
22nd Aug 20223:31 pmRNSHolding(s) in Company
18th Aug 20225:36 pmRNSHolding(s) in Company
18th Aug 20222:10 pmRNSHolding(s) in Company
11th Aug 20224:30 pmEQSHardman & Co Research: Q&A on Tissue Regenix Group plc: Significantly undervalued which should correct
11th Aug 202212:46 pmRNSHolding(s) in Company
11th Aug 202212:17 pmRNSHolding(s) in Company
11th Aug 20227:00 amRNSConfirmation of Interim Results
5th Aug 20223:19 pmRNSHolding(s) in Company
1st Aug 20223:14 pmRNSHolding(s) in Company
19th Jul 20222:30 pmEQSHardman & Co Research : Tissue Regenix (TRX): Strong 1H’22 sales suggest upside potential
19th Jul 20227:00 amRNSHalf Year Trading Update and Notice of Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.